Evidence map›Paper›PMID 41068260›Full record

ArticleScientific reports2025

A multi-phase framework for enhancing diagnostic accuracy and transparency in renal cell carcinoma grading using YOLOv8 and GradCAM.

Amna Bamaqa, Wedad O Alahamade

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amna BamaqaDepartment of Computer Science and Information, Applied College, Taibah University, Madinah, 42353, Saudi Arabia. abamaqa@taibahu.edu.sa.
Wedad O AlahamadeDepartment of Computer Science and Information, Applied College, Taibah University, Madinah, 42353, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney cancer, specifically renal cell carcinoma (RCC), represents a major global health issue, with increasing incidence rates, highlighting the necessity for effective and accurate diagnostic systems. Traditional methods for RCC grading, such as manual histopathological analysis, are labor intensive, susceptible to human error, and lack the scalability required for modern clinical environments. To address these issues, we propose a novel multiphase classification framework that combines YOLOv8 for high-accuracy RCC grading and GradCAM for enhanced model interpretability. The framework progressively refines WHO/ISUP grades through a cascading approach: [Formula: see text] distinguishes between Grades 0/1 and 2/3/4, [Formula: see text] differentiates between Grades 0 and 1, and [Formula: see text] classifies Grades 2, 3, and 4. A unique "Avoid Error Propagation Layer" ensures that only high-confidence predictions are passed to subsequent phases, reducing cumulative errors. Our approach achieves remarkable accuracy (97.51%), precision (93.72%), recall (93.28%), specificity (98.32%), and F1 score (93.35%) on a publicly available RCC dataset. By integrating cutting-edge object detection with visual explanations, our model not only provides superior diagnostic performance but also offers transparent decision-making, which is crucial for clinical adoption. This approach addresses a major shortcoming of existing RCC grading systems by simultaneously prioritizing accuracy and interpretability, promising for revolutionizing kidney cancer diagnosis by enhancing both diagnostic precision and clinician trust.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNeoplasm GradingAlgorithmsHumansGradient-weighted class activation mapping (GradCAM)Histopathology diagnosisKidney cancerRenal cell carcinoma (RCC)You only look once version 8 (YOLOv8)

Identifiers

PMID41068260
PMCPMC12511598

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.